|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis显示文摘 | T. H. Karlsen M. Vesterhus K. M. Boberg | 2014 | Aliment Pharmacol Ther2014，，3： | 2 |
| 2 | The role of pancreatic imaging in monogenic diabetes mellitus 显示文摘 | Haldorsen IS Raeder H Vesterhus M | 2011 | Nat Rev Endocrinol2011，8，3： | 1 |
| 3 | Review article: contro- ve~ies in management of primary biliary cirrhosis and primary sclerosing cholangitis显示文摘 | Kadsen TH Vesterhus M Boberg KM | 2014 | Aliment Pharmacol Ther2014，39，3： | 1 |
| 4 | Review article: controversies in the management of primarybiliary cirrhosis and primary sclerosing cholangitis显示文摘 | Karlsen TH Vesterhus M Boberg KM | 2014 | Aliment Pharmacol Ther2014，39，3： | 1 |
| 5 | Lack of pancreatic body and tail in HNF1B mutation carriers显示文摘 | Haldorsen IS Vesterhus M Raeder H | 2008 | Diabet Med2008，25，7： | 1 |
| 6 | Lack of pancreatic body and tail in HNFIB mutation carriers 显示文摘 | Haldorsen IS Vesterhus M Raeder H | 2008 | Diabet Med2008，25，7： | 1 |
| 7 | Diverse Deletions in the Growth Hormone Receptor Gene Cause Growth Hormone Insensitivity Syndrome显示文摘 | Gastier J M Berg M A Vesterhus P | 2000 | Hum Mutat2000，16，： | 1 |
| 8 | The role of pancreatic imaging in monogenic diabetes mellitus 显示文摘 | Haldorsen IS Rder H Vesterhus M | 2012 | Nat Rev Endocrinol2012，8，3： | 1 |
| 9 | Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4(ITIH4)in Autoimmune Cholestatic Liver Diseases显示文摘Background and Aims:There is an unmet need for new bi-omarkers to improve diagnostics and prognostics in primary biliary cholangitis(PBC)and primary sclerosing cholangitis(PSC).Inter-α-inhibitor heavy chain 4(ITIH4)is an abun-dant,liver-produced protein,and its synthesis may be al-tered in liver diseases.We investigated whether ITIH4 plas-ma concentrations were affected in PBC and PSC patients.Methods:We developed an immunoassay specific for ITIH4 and determined ITIH4 plasma concentrations in 66 PBC,126 PSC,92 autoimmune hepatitis(AIH),67 chronic hepatitis C(CHC),33 alcoholic hepatitis(AH)patients and 138 healthy controls(HCs).Hepatic ITIH4 expression was investigated by immunohistochemistry in PBC.Results:The mean plas-ma concentration of ITIH4 was almost doubled in PBC[409μg/mL(95%CI:388-431)]and 35%higher in PSC[308μg/mL,(95%CI:296-319)]compared with HCs[226μg/mL(95%CI:221-231);p<0.001].In PBC patients,ITIH4 correlated with IgM(rho=0.49,p<0.001).Responders to ursodeoxycholic acid treatment(UDCA)had lower levels of ITIH4 than incomplete responders[395μg/mL(95%CI:364-425)]vs.460μg/mL(95%CI:421-498);p=0.02].Four weeks of UDCA treatment had no effect(p=0.19).In-creased ITIH4 immunohistochemical staining was seen in a liver biopsy from a PBC patient.ITIH4 levels in AIH[224μg/mL(95%CI:208-241)]and HCs were similar(p=0.8).ITIH4 levels were lower in AH[199μg/mL(95%CI:175-223)]and CHC[202μg/mL(192-212)]patients than in HCs(p<0.05).Conclusions:The plasma concentration of ITIH4 was highly elevated in patients with PBC and PSC,suggesting that ITIH4 should be further investigated as a biomarker in cholestatic liver disease. | Tea Lund Laursen Lars Bossen Rasmus Pihl Anne Troldborg Thomas Damgaard Sandahl Annette Gudmann Hansen Trine Folserass Mette Vesterhus Henning Grønbæk Steffen Thiel | 2022 | Journal of Clinical and Translational Hepatology2022，10，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员